ArticleScientific reports2025
Mortality and suicide risk in glaucoma patients with or without vision impairment: a nationwide cohort study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nurses as guardians of time: the hidden clinical value of continuous care in geriatrics.Frontiers in public health · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
This study aimed to investigate the mortality and suicide risk in glaucoma patients with or without vision impairment. Data were retrieved from the Korean National Health Insurance Service for 4,056,650 individuals aged ≥ 20 years and assessed for all-cause and cause-specific mortality for glaucoma from 2009 to 2020. Subjects were classified into 3 groups: healthy control subjects, glaucoma without vision impairment, and glaucoma with vision impairment. Hazard ratios (HR) were calculated under crude and five adjusted models with epidemiologic variables. Analyses of subjects stratified by age and sex were conducted among 3 groups to compare all-cause mortality rate. All-cause mortality significantly increased in both glaucoma without vision impairment ([HR] 3.171, 95% confidence interval [CI] 3.034-3.313) and glaucoma with vision impairment ([HR] 5.397, 95% [CI] 4.824-6.037) groups compared to the control group before adjustment. After adjusting for confounding factors, glaucoma patients with vision impairment showed significantly higher mortality (adjusted HR [aHR] of 1.346 (95% CI, 1.203-1.505). Cause-specific mortality analysis revealed elevated HRs for metabolic, circulatory, respiratory diseases, and suicide-related causes in the glaucoma with vision impairment group before and after adjustment. Of note, both glaucoma without vision impairment and glaucoma with vision impairment groups exhibited progressively increasing aHRs for suicide mortality, with the highest aHR of 2.486 (95% CI, 1.498-4.126) in the glaucoma with vision impairment group. Age and sex-stratified analysis indicated that glaucoma with vision impairment had significantly greater impact on all-cause mortality in younger age groups (P < 0.0001), especially in females (P = 0.0057). Suicide mortality in glaucoma individuals with vision impairment was similar in all age groups (P = 0.827) regardless of sex (P = 0.866). These results showed that overall mortality was increased in glaucoma individuals with vision impairment. In glaucoma without vision impairment, mortality from metabolic diseases and suicide was increased, whereas in glaucoma with vision impairment, mortality from metabolic, circulatory, respiratory diseases, and suicide was increased. Glaucoma with vision impairment had greater impact on overall mortality in younger age groups, especially in females, however, mortality from suicide was increased in all age groups regardless of sex.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.